Read 2019’s most popular cornea/external disease articles
Click Here to Manage Email Alerts
News from the cornea and external disease world included FDA approvals, promising study results and drug pipeline developments in 2019.
Here are the top five most-read cornea/external disease stories of the year from Healio/OSN:
LipiFlow more effective than warm compress for dry eye disease
The systematic review and meta-analysis consisted of 385 patients from four randomized controlled trials that compared the efficacy of a 12-minute vectored thermal pulsation treatment (LipiFlow, Johnson & Johnson Vision) vs. warm compress treatment. Read more.
First neurotrophic keratitis patient treated with Oxervate
Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor that was approved by the FDA in August 2018, has the potential to resolve neurotrophic keratitis in one 8-week treatment cycle. Read more.
CorneaGen acquires KeraLink’s US operations: An exclusive interview with Monty Montoya and Douglas Furlong
CorneaGen and KeraLink announced that CorneaGen would acquire all of KeraLink’s U.S. eye bank operations and related assets. According to a press release, on March 1, 2019, CorneaGen would absorb all of KeraLink’s operating locations and enter into affiliate agreements with KeraLink’s affiliates in New Mexico and San Antonio, and employ most, if not all, of KeraLink’s operations personnel at their current locations. Read more.
Voclosporin ophthalmic solution yields positive results for dry eye
Aurinia Pharmaceuticals’ voclosporin ophthalmic solution demonstrated positive results in an exploratory phase 2 study evaluating the efficacy, safety and tolerability of the treatment for dry eye syndrome. Read more.
FDA approves Avaclyr for herpetic keratitis
Avaclyr (acyclovir ophthalmic ointment 3%), a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated to treat dendritic ulcers in patients with HSV-1 and HSV-2. Read more.